Ignite Creation Date:
2025-12-24 @ 5:32 PM
Ignite Modification Date:
2025-12-28 @ 9:11 AM
Study NCT ID:
NCT07067268
Status:
RECRUITING
Last Update Posted:
2025-07-16
First Post:
2025-07-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Sponsor:
Fudan University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-09-14
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12
Completion Date Type:
ESTIMATED
First Submit Date:
2025-07-05
First Submit QC Date:
None
Study First Post Date:
2025-07-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-05
Last Update Post Date:
2025-07-16
Last Update Post Date Type:
ACTUAL